Attached files

file filename
8-K - FORM 8-K DATED NOVEMBER 5, 2015 - Electromed, Inc.elmd153877_8k.htm
EX-10.1 - BUSINESS LOAN AGREEMENT - Electromed, Inc.elmd153877_ex10-1.htm
EX-10.3 - CHANGE IN TERMS AGREEMENT - Electromed, Inc.elmd153877_ex10-3.htm
EX-99.2 - SHAREHOLDER LETTER DATED NOVEMBER 10, 2015 - Electromed, Inc.elmd153877_ex99-2.htm
EX-10.2 - RIDER TO BUSINESS LOAN AGGREEMENT - Electromed, Inc.elmd153877_ex10-2.htm

 

Exhibit 99.1

 

(ELECTROMED, INC. LOGO)

 

FOR IMMEDIATE RELEASE

 

Contact
Jeremy Brock
Chief Financial Officer
Electromed, Inc.
952-758-9299
investorrelations@electromed.com 

 

Electromed, Inc. Reports Higher First Quarter Revenues and Operating Income

 

Operating Income Increased 47%

 

New Prague, Minnesota – November 10, 2015 - Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for its first quarter ended September 30, 2015.

 

Net revenues for the first quarter of fiscal 2016 were $5.0 million, a 4.8% increase compared to the first quarter of fiscal 2015. Growth in total net revenues was attributable to strong results in the home care market where revenue increased by approximately 12.3%, or $0.5 million, compared to the same period of fiscal 2015. Home care sales increased due to a higher number of approvals and higher average selling price from third party payers, such as insurance companies, Medicare and Medicaid, for the Company’s Smartvest® products.

 

The Company reported net income of $341,000, or $0.04 cents per basic and diluted share, for the first quarter of fiscal 2016, compared to $378,000, or $0.05 per basic and diluted share, for the same period of fiscal 2015. The decrease in net income was primarily the result of recording current tax expense in fiscal 2016, mostly offset by increased revenue and reductions in cost of goods sold expenses year over year. The first quarter of fiscal 2015 benefitted from the Company’s use of its tax loss carryforwards, combined with a valuation allowance on net deferred tax assets, which eliminated income tax expense. In the first quarter of fiscal 2016, the Company reported income tax expense of $224,000. Net income before income tax expense rose $187,000 or 49.6%, compared to the first quarter of the prior fiscal year.

 

Gross margins in the first quarter of fiscal 2016 were 77.2%, up from 69.1% in the first quarter of fiscal 2015. The increase in gross profit percentage resulted primarily from the increase in domestic home care revenue The increase in gross profit dollars resulted from the increase in domestic home care revenue at higher average selling price and greater referral to approval percentage, as compared with the prior year, along with lower manufacturing costs due to the decrease in our manufacturing costs of the Smartvest SQL. Operating expenses, which include selling, general and administrative as well as research and development expenses, in the first quarter of fiscal 2016, were $3.3 million or 65.5% of revenue compared with $2.9 million or 60.7% of revenue in the same period of the prior year. The increase was due to a combination of additional employees in our sales and sales support departments, consulting fees associated with information technology improvements and outsourcing certain IT services.

 

Commenting on the first quarter results, Kathleen Skarvan, President and Chief Executive Officer of the Company said, “The Company continues to make steady gains and I’m particularly pleased with margin performance and pretax income growth. While showing positive trends, revenue growth as compared to the prior quarter was affected by the timing of some referrals and approvals from third party payers. We estimate continued revenue growth in fiscal 2016 as the addition of sales resources provides a larger and more diverse base of sales opportunities. Quarterly revenues may fluctuate though based on the referral mix of payers. I am very pleased with the improvement in gross margin we reported as it reflects higher average selling price from third party payers in our home care and the progress we have made in lowering the manufacturing cost of our newest generation device, Smartvest SQL. Sales and marketing expenses grew as planned. Overall, it was a solid quarter that continues momentum we have worked hard to create and we will look to build on that momentum as fiscal 2016 progresses.”

 

 
 

 

Electromed, Inc.

 

Results for the Three Months Ended September 30, 2015

 

Page 2 

 

About Electromed, Inc.

 

Electromed, Inc. develops, manufactures, markets, and sells innovative products that provide airway clearance therapy, including the Smartvest® Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Further information about the Company can be found at www.electromed.com. 

 

Cautionary Statements

 

Certain statements in this release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words “anticipate,” “believe,” “estimate,” “expect,” “will” and similar words. Forward-looking statements in this release include estimated revenue trends, changes in sales opportunities and planned expenses. Forward-looking statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known and unknown, associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to, the impact of emerging and existing competitors, the effect of new legislation on our industry and business, the effectiveness of our sales and marketing and cost control initiatives, changes to reimbursement programs, as well as other factors described from time to time in our reports to the Securities and Exchange Commission (including our most recent Annual Report on Form 10-K, as amended from time to time, and subsequent reports on Form 10-Q and Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this release.

 

Financial Tables Follow:

 

-more- 

  

 
 

 

Electromed, Inc.
Condensed Balance Sheets

 

   September 30, 2015   June 30, 2015 
   (Unaudited)     
Assets          
Current Assets          
Cash   $3,782,977   $3,598,240 
Accounts receivable (net of allowances for doubtful accounts of $45,000)    6,457,302    6,518,816 
Inventories    2,155,305    2,072,108 
Prepaid expenses and other current assets    501,036    397,833 
Total current assets    12,896,620    12,586,997 
Property and equipment, net    3,571,833    3,635,516 
Finite-life intangible assets, net    975,149    999,842 
Other assets    181,762    182,699 
Total assets   $17,625,364   $17,405,054 
           
Liabilities and Shareholders’ Equity          
Current Liabilities          
Current maturities of long-term debt   $49,409   $48,749 
Accounts payable    522,011    538,518 
Accrued compensation    501,135    700,370 
Income tax payable   147,181    122,657 
Warranty reserve    630,000    660,000 
Other accrued liabilities    282,258    208,983 
Total current liabilities    2,131,994    2,279,277 
Long-term debt, less current maturities    1,189,928    1,202,446 
Total liabilities    3,321,922    3,481,723 
           
Commitments and Contingencies          
           
Equity          
Common stock, $0.01 par value; authorized: 13,000,000 shares; 8,163,857 and 8,133,857 issued and outstanding at September 30, 2015 and June 30, 2015, respectively    81,639    81,339 
Additional paid-in capital    13,366,169    13,327,320 
Retained earnings    855,634    514,672 
Total shareholders’ equity    14,303,442    13,923,331 
Total liabilities and shareholders’ equity   $17,625,364   $17,405,054 

 

 
 

 

Electromed, Inc.
Condensed Statements of Operations (Unaudited)

 

   Three Months Ended September 30, 
   2015   2014 
Net revenues   $5,001,188   $4,770,539 
Cost of revenues    1,141,758    1,475,797 
Gross profit    3,859,430    3,294,742 
           
Operating expenses          
Selling, general and administrative    3,232,719    2,821,495 
Research and development    41,543    75,265 
Total operating expenses    3,274,262    2,896,760 
Operating income   585,168    397,982 
           
Interest expense, net of interest income of $624 and $1,212 respectively    20,206    20,453 
Net income before income taxes    564,962    377,529 
           
Income tax expense    (224,000)   —   
Net income   $340,962   $377,529 
           
Income per share:          
Basic   $0.04   $0.05 
Diluted   $0.04   $0.05 
           
           
Weighted-average common shares outstanding:          
Basic    8,133,857    8,114,252 
Diluted    8,173,684    8,114,252 

 

 
 

 

Electromed, Inc.
Condensed Statements of Cash Flows (Unaudited)

 

   Three Months Ended September 30, 
   2015   2014 
Cash Flows From Operating Activities          
Net income   $340,962   $377,529 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation    154,849    155,341 
Amortization of finite-life intangible assets    30,674    30,892 
Amortization of debt issuance costs    4,664    4,942 
Share-based compensation expense    39,149    15,089 
Loss on disposal of property and equipment and intangibles assets    24,965    18,824 
Changes in operating assets and liabilities:          
Accounts receivable    61,514    125,578 
Inventories    (67,144)   (7,702)
Prepaid expenses and other assets    (106,930)   (80,750)
Accounts payable and accrued liabilities    (171,273)   314,901 
Net cash provided by operating activities    311,430    954,644 
           
Cash Flows From Investing Activities          
Expenditures for property and equipment    (101,006)   (156,669)
Expenditures for finite-life intangible assets    (13,829)   (9,320)
Net cash used in investing activities    (114,835)   (165,989)
           
Cash Flows From Financing Activities          
Principal payments on long-term debt including capital lease obligations    (11,858)   (11,231)
Net increase in cash    184,737    777,424 
Cash          
Beginning of period    3,598,240    1,502,702 
End of period   $3,782,977   $2,280,126